 |
 |
|
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Aspirin for the Prevention of Heart Attacks in People without Previous Cardiovascular Events: Recommendations from the United States Preventive Services Task Force
15 January 2002 | Volume 136 Issue 2 | Page I55
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full reports titled "Aspirin for the Primary Prevention of Cardiovascular Events: Recommendation and Rationale" and "Aspirin for the Primary Prevention of Cardiovascular Events: A Summary of the Evidence for the U.S. Preventive Services Task Force." They are in the 15 January 2002 issue of Annals of Internal Medicine (volume 136, pages 157-160 and pages 161-172). The first report was written by the U.S. Preventive Services Task Force; the second report was written by M Hayden, M Pignone, C Phillips, and C Mulrow.
What is the United States Preventive Services Task Force?
The United States Preventive Services Task Force (USPSTF) is a group of health experts that reviews published research and makes recommendations about preventive health care.
What is the problem and what is known about it so far?
Heart attack ("myocardial infarction") occurs when blockage develops in the blood vessels that supply the heart muscle. Heart attacks are one of the most common causes of illness and are the leading cause of death in the United States. Certain conditions ("risk factors") increase a person's chance of having a heart attack. They include older age, male sex, high blood pressure, diabetes, smoking, high total or LDL ("bad") cholesterol levels, low HDL ("good") cholesterol levels, and close relatives with heart attacks before age 60. Aspirin decreases the chances of a heart attack in people who have had previous heart attacks or strokes, but its usefulness in people without such a history is unclear. Aspirin can have uncommon but serious complications, such as bleeding in the digestive tract or in the brain.
How did the USPSTF develop these recommendations?
The USPSTF reviewed published research to measure the benefits and harms of aspirin use in adults who have never had a heart attack or stroke.
What did the authors find?
There is good evidence that aspirin decreases heart attacks in people who do not have cardiovascular disease but do have heart attack risk factors. The more risk factors a person has, the more heart attacks aspirin prevents. However, taking aspirin increases a person's chances of complications, such as bleeding in the digestive tract or brain. Complications are most likely in people who have uncontrolled high blood pressure or who take blood thinners or anti-inflammatory drugs in addition to aspirin.
What does the USPSTF suggest that patients do?
Adult patients who have cardiovascular risk factors should discuss the benefits and harms of aspirin to prevent cardiovascular events with their doctors. Patients and doctors can use a tool located at http://www.med-decisions.com to calculate a person's risk of a future heart attack. If a patient's chance of having a heart attack over the next 5 years is at least 3 out of 100 (3%), then the benefits of aspirin are likely to outweigh the harms. However, there is no single correct answer for all patients. The decision to take aspirin or not will depend on the patient's feelings about avoiding heart attacks while risking the possible complications of bleeding in the digestive tract or brain.
What are the cautions related to these recommendations?
Participants in the studies that the USPSTF used to develop the recommendations were mostly men who were 40 to 75 years of age. Estimates of benefits and harms may not be reliable for women or for older men.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  American Diabetes Association Standards of Medical Care in Diabetes--2009 Diabetes Care, January 1, 2009; 32(Supplement_1): S13 - S61. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Spring Health Decision Making: Lynchpin of Evidence-Based Practice Med Decis Making, November 1, 2008; 28(6): 866 - 874. [Abstract] [PDF]
|
|
|
|
|
|
I. B. Hirsch, S. E. Inzucchi, and M. S. Kirkman Standards of Medical Care in Diabetes--2008: Response to Dora, Kramer, and Canani Diabetes Care, May 1, 2008; 31(5): e45 - e45. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Patrono and B. Rocca Aspirin: Promise and Resistance in the New Millennium Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): s25 - s32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
American Diabetes Association Standards of Medical Care in Diabetes--2008 Diabetes Care, January 1, 2008; 31(Supplement_1): S12 - S54. [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Glynn, P. M Ridker, S. Z. Goldhaber, and J. E. Buring Effect of Low-Dose Aspirin on the Occurrence of Venous Thromboembolism: A Randomized Trial Ann Intern Med, October 16, 2007; 147(8): 525 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ardoin, C. Sandborg, and L. Schanberg Review: Management of dyslipidemia in children and adolescents with systemic lupus erythematosus Lupus, August 1, 2007; 16(8): 618 - 626. [Abstract] [PDF]
|
|
|
|
 |
|
 E. M. Hylek, C. Evans-Molina, C. Shea, L. E. Henault, and S. Regan Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation Circulation, May 29, 2007; 115(21): 2689 - 2696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Cohen and P. J. Neumann What's More Dangerous, Your Aspirin Or Your Car? Thinking Rationally About Drug Risks (And Benefits) Health Aff., May 1, 2007; 26(3): 636 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Jacobs, M. J. Thun, E. B. Bain, C. Rodriguez, S. J. Henley, and E. E. Calle A Large Cohort Study of Long-Term Daily Use of Adult-Strength Aspirin and Cancer Incidence J Natl Cancer Inst, April 18, 2007; 99(8): 608 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Rippe, T. J. Angelopoulos, and L. Zukley Lifestyle Medicine Strategies for Risk Factor Reduction, Prevention, and Treatment of Coronary Heart Disease: Part II American Journal of Lifestyle Medicine, March 1, 2007; 1(2): 79 - 90. [Abstract] [PDF]
|
|
|
|
|
|
American Diabetes Association Standards of Medical Care in Diabetes--2007 Diabetes Care, January 1, 2007; 30(suppl_1): S4 - S41. [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Sequist, R. Marshall, S. Lampert, E. J. Buechler, and T. H. Lee Missed opportunities in the primary care management of early acute ischemic heart disease. Arch Intern Med, November 13, 2006; 166(20): 2237 - 2243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. O'Kennedy, L. Crosbie, S. Whelan, V. Luther, G. Horgan, J. I Broom, D. J Webb, and A. K Duttaroy Effects of tomato extract on platelet function: a double-blinded crossover study in healthy humans. Am. J. Clinical Nutrition, September 1, 2006; 84(3): 561 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Hennekens, O. Sechenova, D. Hollar, and V. L. Serebruany Dose of Aspirin in the Treatment and Prevention of Cardiovascular Disease: Current and Future Directions. Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2006; 11(3): 170 - 176. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Hur, A. T Chan, A. C Tramontano, and G S. Gazelle Coxibs Versus Combination NSAID and PPI Therapy for Chronic Pain: An Exploration of the Risks, Benefits, and Costs Ann. Pharmacother., June 1, 2006; 40(6): 1052 - 1063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pignone, S. Earnshaw, J. A. Tice, and M. J. Pletcher Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med, March 7, 2006; 144(5): 326 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Berger, M. C. Roncaglioni, F. Avanzini, I. Pangrazzi, G. Tognoni, and D. L. Brown Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-analysis of Randomized Controlled Trials JAMA, January 18, 2006; 295(3): 306 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Bhatt, P. G. Steg, E. M. Ohman, A. T. Hirsch, Y. Ikeda, J.-L. Mas, S. Goto, C.-S. Liau, A. J. Richard, J. Rother, et al. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis JAMA, January 11, 2006; 295(2): 180 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Blann Antiplatelet therapy and the vascular tree Heart, January 1, 2006; 92(1): 3 - 4. [Full Text] [PDF]
|
|
|
|
|
|
American Diabetes Association Standards of Medical Care in Diabetes-2006 Diabetes Care, January 1, 2006; 29(suppl_1): S4 - S42. [Full Text] [PDF]
|
|
|
|
|
|
Prepared by: British Cardiac Society, British Hype JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice Heart, December 1, 2005; 91(suppl_5): v1 - v52. [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Hall and N. Dalbeth Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology, December 1, 2005; 44(12): 1473 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W Eikelboom Warfarin was not more effective than aspirin and increased adverse events in symptomatic intracranial arterial stenosis Evid. Based Med., October 1, 2005; 10(5): 136 - 136. [Full Text] [PDF]
|
|
|
|
|
|
J. W Eikelboom Low dose aspirin lowered stroke risk but not risks of MI or cardiovascular deaths in women Evid. Based Med., October 1, 2005; 10(5): 137 - 137. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chen Low-dose aspirin: Major benefits, minimal cost Am. J. Health Syst. Pharm., July 1, 2005; 62(13): 1357 - 1357. [Full Text] [PDF]
|
|
|
|
|
|
J. J. Saseen ASHP Therapeutic Position Statement on the Daily Use of Aspirin for Preventing Cardiovascular Events Am. J. Health Syst. Pharm., July 1, 2005; 62(13): 1398 - 1405. [Full Text] [PDF]
|
|
|
|
 |
|
 P. M Ridker, N. R. Cook, I-M. Lee, D. Gordon, J. M. Gaziano, J. E. Manson, C. H. Hennekens, and J. E. Buring A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women N. Engl. J. Med., March 31, 2005; 352(13): 1293 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Hur, L. S Simon, and G S. Gazelle Analysis of Aspirin-Associated Risks in Healthy Individuals Ann. Pharmacother., January 1, 2005; 39(1): 51 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
American Diabetes Association Standards of Medical Care in Diabetes Diabetes Care, January 1, 2005; 28(suppl_1): S4 - S36. [Full Text] [PDF]
|
|
|
|
|
|
S. D. Persell and D. W. Baker Aspirin Use Among Adults With Diabetes: Recent Trends and Emerging Sex Disparities Arch Intern Med, December 13, 2004; 164(22): 2492 - 2499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 234S - 264S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Cox, M. Frisse, A. Behm, and K. A. Fairman Over-the-Counter Pain Reliever and Aspirin Use Within a Sample of Long-term Cyclooxygenase 2 Users Arch Intern Med, June 14, 2004; 164(11): 1243 - 1246. [Full Text] [PDF]
|
|
|
|
|
|
P. A. Howard and P. Delafontaine Nonsteroidal Anti-Inflammatory drugs and cardiovascular risk J. Am. Coll. Cardiol., February 18, 2004; 43(4): 519 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Hur, N. S. Nishioka, and G. S. Gazelle Cost-Effectiveness of Aspirin Chemoprevention for Barrett's Esophagus J Natl Cancer Inst, February 18, 2004; 96(4): 316 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Chan, E. L. Giovannucci, E. S. Schernhammer, G. A. Colditz, D. J. Hunter, W. C. Willett, and C. S. Fuchs A Prospective Study of Aspirin Use and the Risk for Colorectal Adenoma Ann Intern Med, February 3, 2004; 140(3): 157 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Standards of Medical Care in Diabetes Diabetes Care, January 1, 2004; 27(90001): s15 - 35. [Full Text] [PDF]
|
|
|
|
|
|
Aspirin Therapy in Diabetes Diabetes Care, January 1, 2004; 27(90001): s72 - 73. [Full Text] [PDF]
|
|
|
|
|
|
M. Sacco, F. Pellegrini, M. C. Roncaglioni, F. Avanzini, G. Tognoni, and A. Nicolucci Primary Prevention of Cardiovascular Events With Low-Dose Aspirin and Vitamin E in Type 2 Diabetic Patients: Results of the Primary Prevention Project (PPP) trial Diabetes Care, December 1, 2003; 26(12): 3264 - 3272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Colwell Aspirin for Primary Prevention of Cardiovascular Events in Diabetes Diabetes Care, December 1, 2003; 26(12): 3349 - 3350. [Full Text] [PDF]
|
|
|
|
|
|
J. E Shaw Chemoprophylaxis with aspirin (81 mg daily) reduced the incidence of colorectal adenomas in people at risk Evid. Based Med., November 1, 2003; 8(6): 178 - 179. [Full Text] [PDF]
|
|
|
|
|
|
J. E Shaw Aspirin prevented new colorectal adenomas in patients with previous colorectal cancer Evid. Based Med., November 1, 2003; 8(6): 179 - 179. [Full Text] [PDF]
|
|
|
|
|
|
R. S. Eidelman, P. R. Hebert, S. M. Weisman, and C. H. Hennekens An Update on Aspirin in the Primary Prevention of Cardiovascular Disease Arch Intern Med, September 22, 2003; 163(17): 2006 - 2010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Morrell Initiating antiplatelet therapy in diabetes: a PCO view The British Journal of Diabetes & Vascular Disease, September 1, 2003; 3(5): 349 - 353. [Abstract] [PDF]
|
|
|
|
|
|
J. G. Canto and A. E. Iskandrian Major Risk Factors for Cardiovascular Disease: Debunking the "Only 50%" Myth JAMA, August 20, 2003; 290(7): 947 - 949. [Full Text] [PDF]
|
|
|
|
|
|
B. M.R. Spiegel, L. Targownik, G. S. Dulai, and I. M. Gralnek The Cost-Effectiveness of Cyclooxygenase-2 Selective Inhibitors in the Management of Chronic Arthritis Ann Intern Med, May 20, 2003; 138(10): 795 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Przyklenk and G. Heusch Late preconditioning against myocardial stunning: Does aspirin close the "second window" of endogenous cardioprotection? J. Am. Coll. Cardiol., April 2, 2003; 41(7): 1195 - 1197. [Full Text] [PDF]
|
|
|
|
|
|
G. E. McLaughlin Aspirin for the Primary Prevention of Cardiovascular Events Ann Intern Med, October 1, 2002; 137(7): 622 - 623. [Full Text] [PDF]
|
|
|
|
|
|
T. A. Pearson, S. N. Blair, S. R. Daniels, R. H. Eckel, J. M. Fair, S. P. Fortmann, B. A. Franklin, L. B. Goldstein, P. Greenland, S. M. Grundy, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases Circulation, July 16, 2002; 106(3): 388 - 391. [Full Text] [PDF]
|
|
|
|
|
|
M. Jain and M. Rosenberg Review: aspirin reduces CAD events in people with no history of cardiovascular disease, but it increases gastrointestinal bleeding Evid. Based Med., July 1, 2002; 7(4): 111 - 111. [Full Text] [PDF]
|
|
|
|
|
|
M. S. Lauer Aspirin for Primary Prevention of Coronary Events N. Engl. J. Med., May 9, 2002; 346(19): 1468 - 1474. [Full Text] [PDF]
|
|
|
|
|
|
G. Lowe Review: Which patients with diabetes should receive which antiplatelet agents? The British Journal of Diabetes & Vascular Disease, May 1, 2002; 2(3): 157 - 160. [Abstract] [PDF]
|
|
|
|
 |
|
 Guidelines: Aspirin for Primary Prevention of Adverse Cardiovascular Events Journal Watch Cardiology, February 22, 2002; 2002(222): 1 - 1. [Full Text]
|
|
|
|
 |
|
 Aspirin for Primary Prevention: Trade-Off Between Bleeding and Prevention of Cardiovascular Events Journal Watch (General), February 1, 2002; 2002(201): 2 - 2. [Full Text]
|
|
|
Article
